169 related articles for article (PubMed ID: 10326962)
21. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Fujishima H; Ohashi Y; Takamura E
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
[TBL] [Abstract][Full Text] [Related]
22. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells.
Sharif NA; Wiernas TK; Griffin BW; Davis TL
Br J Pharmacol; 1998 Nov; 125(6):1336-44. PubMed ID: 9863665
[TBL] [Abstract][Full Text] [Related]
24. Allergic conjunctivitis: a survey of new antihistamines.
Berdy GJ; Abelson MB; George MA; Smith LM; Giovanoni RL
J Ocul Pharmacol; 1991; 7(4):313-24. PubMed ID: 1687324
[TBL] [Abstract][Full Text] [Related]
25. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
Secchi A; Leonardi A; Discepola M; Deschenes J; Abelson MB
Acta Ophthalmol Scand Suppl; 2000; (230):48-51. PubMed ID: 11057351
[TBL] [Abstract][Full Text] [Related]
26. H1-Receptor Antagonist Olopatadine Inhibits MUC5AC Secretion by Conjunctival Goblet Cells.
He M; Qin W; Wu Y; Wang X; Wang Y; Wang X
Bull Exp Biol Med; 2021 Oct; 171(6):750-754. PubMed ID: 34709518
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
29. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
30. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
31. Niflumic Acid Reduces Histamine-Induced MUC5AC Expression in Human Conjunctival Epithelial Cells.
Seo KY; Jeon S; Choi SH; Chung SH
Ophthalmic Res; 2011 Oct; 46(4):181-6. PubMed ID: 21447991
[TBL] [Abstract][Full Text] [Related]
32. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
[TBL] [Abstract][Full Text] [Related]
33. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine.
Feinberg G; Stokes TC
Int Arch Allergy Appl Immunol; 1987; 82(3-4):537-8. PubMed ID: 2883131
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
35. Histamine receptors and the conjunctiva.
Bielory L; Ghafoor S
Curr Opin Allergy Clin Immunol; 2005 Oct; 5(5):437-40. PubMed ID: 16131920
[TBL] [Abstract][Full Text] [Related]
36. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
[TBL] [Abstract][Full Text] [Related]
37. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis.
Abelson MB; Weintraub D
Eur J Ophthalmol; 1994; 4(2):91-101. PubMed ID: 7950341
[TBL] [Abstract][Full Text] [Related]
38. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
Noble S; McTavish D
Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
[TBL] [Abstract][Full Text] [Related]
39. Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.
Tamura T
Asia Pac Allergy; 2012 Apr; 2(2):115-21. PubMed ID: 22701861
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells.
Molet S; Gosset P; Lassalle P; Czarlewski W; Tonnel AB
Clin Exp Allergy; 1997 Oct; 27(10):1167-74. PubMed ID: 9383257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
